FIELD: biotechnology.
SUBSTANCE: present invention relates to novel species-selective phage endolysins and their use for treating bacterial vaginosis (BV). Present invention provides recombinant endolysins, that is endolysins with substituted domains. Invention also relates to said endolysins for use in treating diseases or disorders, such as bacterial infections, particularly BV. Invention also relates to polynucleotides coding said endolysins. Said polynucleotides can also be used to treat such diseases or disorders. Present invention also discloses a pharmaceutical composition containing endolysin according to the present invention for use in treating such diseases or disorders. Said endolysins, polynucleotides and the pharmaceutical composition can be administered locally, particularly locally in the vagina.
EFFECT: invention provides methods of treating, decontaminating or detecting bacterial infections and disorders associated with Gardnerella.
27 cl, 16 dwg, 7 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGENIC RECEPTORS (SCCAR) FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2731543C2 |
| MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
| TRISPECIFIC BINDING MOLECULES FOR TREATING VIRAL HEPATITIS B INFECTION AND BOUND STATES | 2016 |
|
RU2733496C2 |
| IMPROVED VARIABLE DOMAINS OF IMMUNOGLOBULINS | 2015 |
|
RU2746738C2 |
| BISPECIFIC ANTIBODIES BINDING TO TFR | 2019 |
|
RU2810756C2 |
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| TNF-α BINDING POLYPEPTIDE AND METHOD FOR TREATMENT OF TNF-α RELATED DISEASES | 2017 |
|
RU2794974C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
